Other Diseases

Bayer AG and Evotec AG enter a multi-target research partnership agreement Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement, Bayer will have all the rights to select clinical candidates and Evotec’s Cure Nephron target pipeline. It will pay approximately $15.64m to Evotec during the contract period. Plasticell and CellSpring AG have entered into an agreement Plasticell and CellSpring have entered an agreement which aims to examine and validate the capability of osteogenic cell therapy and 3D cell cultures in drug screening. According to this agreement, the companies will be responsible...